Payment overview · 2025
General Payments
$1,142.75
47 reported records · 17 companies
Healthcare provider profile · identity verified
Ogleh I Nesheiwat, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOPEWELL JUNCTION, NY · NPI 1194809145
Verified facts
What the public records show
CMS Open Payments records show Ogleh I Nesheiwat, MD received $1,142.75 in general payments during 2025 across 47 reported records.
Lilly USA, LLC accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $173.18 | 15.2% | 9 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $125.00 | 10.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $107.92 | 9.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $98.74 | 8.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.36 | 8.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $90.01 | 7.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65.77 | 5.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.85 | 5.3% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $53.79 | 4.7% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$47.33 | 4.1% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $46.57 | 4.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.19 | 3.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.91 | 3.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.06 | 3.2% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $21.94 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.88 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.25 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,142.75 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $144.83 | 6 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $112.57 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $90.01 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $78.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.54 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.37 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $65.77 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.85 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $53.79 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.54 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $47.33 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $46.57 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.23 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 307 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 143 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
87 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 42 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1194 | 334 |
| Amlodipine Besylate | Amlodipine Besylate | 530 | 130 |
| Metformin Hcl | Metformin Hcl | 446 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 84 |
| Gabapentin | Gabapentin | 345 | 83 |
| Lisinopril | Lisinopril | 345 | 89 |
| Eliquis | Apixaban | 307 | 42 |
| Furosemide | Furosemide | 275 | 48 |
| Omeprazole | Omeprazole | 270 | 78 |
| Losartan Potassium | Losartan Potassium | 256 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 48 |
| Ozempic | Semaglutide | 153 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 61 |
| Montelukast Sodium | Montelukast Sodium | 144 | 79 |
| Jardiance | Empagliflozin | 143 | 42 |
| Donepezil Hcl | Donepezil Hcl | 139 | 19 |
| Simvastatin | Simvastatin | 136 | 30 |
| Azithromycin | Azithromycin | 125 | 109 |
| Alprazolam | Alprazolam | 124 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 71 |
| Potassium Chloride | Potassium Chloride | 122 | 25 |
| Carvedilol | Carvedilol | 103 | 29 |
| Ezetimibe | Ezetimibe | 101 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 101 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 22 |
| Atenolol | Atenolol | 88 | 15 |
| Farxiga | Dapagliflozin Propanediol | 87 | 26 |
| Glipizide Er | Glipizide | 85 | 19 |
| Hydrocortisone | Hydrocortisone | 84 | 67 |
| Sertraline Hcl | Sertraline Hcl | 83 | 14 |
| Memantine Hcl | Memantine Hcl | 78 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 76 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 17 |
| Mounjaro | Tirzepatide | 72 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 68 | 18 |
| Tramadol Hcl | Tramadol Hcl | 67 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 15 |
| Allopurinol | Allopurinol | 61 | 19 |
| Famotidine | Famotidine | 60 | 19 |
| Meclizine Hcl | Meclizine Hcl | 60 | 31 |
| Finasteride | Finasteride | 58 | 16 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 54 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 13 |
| Synthroid | Levothyroxine Sodium | 52 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 13 |
| Metformin Hcl Er | Metformin Hcl | 49 | 16 |
| Alendronate Sodium | Alendronate Sodium | 48 | 13 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 46 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 33 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Glipizide | Glipizide | 43 | 13 |
| Mirtazapine | Mirtazapine | 43 | 13 |
| Prednisone | Prednisone | 42 | 25 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 18 |
| Spironolactone | Spironolactone | 40 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Glimepiride | Glimepiride | 38 | 13 |
| Lidocaine | Lidocaine | 36 | 26 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Nystatin | Nystatin | 34 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 26 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 25 |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Naproxen | Naproxen | 29 | 17 |
| Nyamyc | Nystatin | 29 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 26 | suppressed |
| Lactulose | Lactulose | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Valsartan | Valsartan | 26 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | 11 |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Wegovy | Semaglutide | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Ofloxacin | Ofloxacin | 22 | 21 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | 13 |
| Clonidine | Clonidine | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | 12 |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Procrit | Epoetin Alfa | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,142.75 · 47 records | Lilly USA, LLC | ACCRUFER, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, LIBTAYO, Leqembi, MINIMED 780G, MOUNJARO, NURTEC ODT, Omnipod, Ozempic, PAXLOVID, REXULTI, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error